Lexicon Pharma (LXRX) Tops Q4 EPS by 29c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Lexicon Pharma (LXRX) Tops Q4 EPS by 29c, Revenues Miss

LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

March 12, 2020 7:00 AM EDT

XERMELO® (telotristat ethyl) 2019 U.S. Net Sales Reached $31.0 Million

THE WOODLANDS, Texas, March 12, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2019 and provided a business update.

In 2019, we achieved continued growth in our XERMELO (telotristat ethyl)... More